Formycon Gets UK Nod For Eylea Biosimilar

Teva-Partnered Ahzantive Version Of Aflibercept Receives MHRA Approval

03 Mar 2025

Formycon has celebrated receiving a UK approval for its Ahzantive biosimilar version of Eylea, setting up a launch from partner Teva – which has already seen success in the UK market with the partners’ Lucentis biosimilar, Ongavia.

Formycon has another UK ophthalmic biosimilar approval (Shutterstock)

Formycon has received approval from the UK Medicines and Healthcare products Regulatory Agency for its FYB203 aflibercept biosimilar rival to Eylea, with the product approved under the name Ahzantive.

The ophthalmic biosimilar – approved to treat age-related neovascular (wet) macular degeneration, diabetic macular edema, visual impairment due to myopic...